• 中国科技论文统计源期刊(中国科技核心期刊)
  • 中国医药卫生核心期刊
  • 中国抗癌协会系列期刊
LEI Jun, FAN Yu-xiang, HE Wen-ting, ZENG Fang-ye, SUN Qi, ZHANG Hong-liang. Meta Analysis of the Combination of TACE and Resection for Treatment of HCC in Chinese[J]. Journal of Evidence-Based Medicine, 2015, 15(3): 168-176. DOI: 10.3969/j.issn.1671-5144.2015.03.013
Citation: LEI Jun, FAN Yu-xiang, HE Wen-ting, ZENG Fang-ye, SUN Qi, ZHANG Hong-liang. Meta Analysis of the Combination of TACE and Resection for Treatment of HCC in Chinese[J]. Journal of Evidence-Based Medicine, 2015, 15(3): 168-176. DOI: 10.3969/j.issn.1671-5144.2015.03.013

Meta Analysis of the Combination of TACE and Resection for Treatment of HCC in Chinese

More Information
  • Received Date: November 17, 2014
  • Published Date: June 29, 2015
  • Objective To evaluate the transarterial chemoembolization(TACE) in preventing recurrence and improving Chinese patient’s survival after curative resection for hepatocellular carcinoma (HCC) by using a meta-analysis. Methods Relevant randomized controlled trials (RCTs)related to TACE treatment after HCC resection were searched using PubMed, Cochrane Library, ISI Web of Knowledge, CBM, CNKI and VIP from inception to September 2014. RevMan5.0 was applied for the meta-analysis. After heterogeneity analysis, pooled risk ratio (RR) with 95% confidence interval (95%CI) using both fixed and random effect models were estimated. Sensitivity analyses were used for evaluating the robustness of the result. Publication bias was assessed by map funnel method. Results A total of 14 RCTs involving 1 029 patients were included, 467 cases of patients with hepatectomy plus TACE, 462 patients with hepatectomy alone. All were evaluated by the Jadad scale, 4 items of high quality research, 10 low quality research. Compared with hepatectomy only, the RR (95%CI) of the recurrence at 1, 2 and 3 years after the resection in case group were 0.48 (95%CI 0.37~0.63), 0.62(0.50~0.77) and 0.50 (0.45~0.84), which all had statistic significance reflecting that postoperative adjuvant TACE could reduce recurrence rate. Postoperative adjuvant TACE seems to improve the overall survival (OS) rate for 1 year, 2 years and 3 years than hepatectomy only, RR and 95%CI: 1.37 (1.23~1.54), 1.66(1.36~2.04) and 1.36 (1.51~2.77), But the differences of disease-free survival (DFS) rate between the two groups were not significance. Side effects and severe adverse events related with TACE were mainly liver function impairment, fever and gastrointestinal symptoms. Conclusions Based on the results of this meta analysis, postoperative adjuvant TACE could reduce the recurrence rate and improve the OS of HCC, but may not DFS of patients. However, more RCTs with high quality are still needed to assess and verify the efficacy and safety further.
  • [1]
    Yang JD, Roberts LR. Hepatocellular carcinoma: A global view[J]. Nat Rev Gastroenterol Hepatol, 2010,7(8): 448-458.
    [2]
    Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014,64(1): 9-29.
    [3]
    Lai EC. Lau WY. The continuing challenge of hepatic cancer in Asia[J]. Surgeon, 2005,3(3): 210-215.
    [4]
    施海彬. 介入放射诊疗策略[M]. 北京: 科学出版社, 2008: 174.
    [5]
    Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011][EB/OL]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
    [6]
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses[J]. BMJ, 2003,327(7414): 557-560.
    [7]
    Li JQ, Zhang YQ, Zhang WZ, et al. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy[J]. J Cancer Res Clin Oncol, 1995,121(6): 364-366.
    [8]
    林建华, 贺旭,李朝龙. 术后栓塞化疗对大肝癌切除后远期疗效的观察[J]. 外科理论与实践, 1998,3(3): 181-182.
    [9]
    Lai EC, Lo CM, Fe ST, et al. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial[J]. Arch Surg, 1998,133(2): 183-188.
    [10]
    Zhou W, Wu M, Yao XP, et al. The effects of combined hepatectomy and immunochemotherapy on postoperative recurrence of primary liver cancer[J]. The Chinese-German Journal of Clinical Oncology, 2002,1(3): 163-165.
    [11]
    张国生, 李小明, 王向,等. 肝动脉栓塞化疗 (TACE) 对肝癌切除术后复发的影响[J]. 赣南医学院学报, 2005,24(6): 718-719.
    [12]
    Li Q, Wang J, Sun Y, et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: A randomized study with 131 cases[J]. Dig Surg, 2006,23(4): 235-240.
    [13]
    刘方, 郭秀英, 李保国,等. 选择性肝动脉化疗栓塞术对 30 例肝癌根治术后预防复发的疗效评价[J]. 中国肿瘤临床, 2007,34(8): 454-456.
    [14]
    张坤, 江艺, 张绍庚, 等. 肝动脉化疗栓塞对原发性肝癌患者术后生存及肿瘤复发的影响[J]. 中国普通外科杂志, 2007, 16(3): 206-208.
    [15]
    Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg, 2009,198(3): 313-318.
    [16]
    Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage ⅢA hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2009, 135(10): 1437-1445.
    [17]
    余正平,徐正铿,曾其强,等. 原发性肝癌根治术后辅助肝动脉栓塞化疗预防肝内复发的疗效分析[C]. 2008年浙江省外科学术年会论文汇编, 2008.
    [18]
    韩绍磊,郑昭敏,张海涛,等. 肝动脉化疗栓塞对原发性肝癌患者术后复发率及生存率的影响[J]. 现代预防医学, 2010,37(18): 3591-3592.
    [19]
    马超,庞春,丁月超. 定期经门静脉化疗与经肝动脉栓塞化疗对肝癌切除术后复发的预防作用比较[J]. 临床医学, 2011, 31(3): 45-46.
    [20]
    徐峰,黄杨卿,李叶晟,等. 小肝细胞癌术后是否常规需要辅助性肝动脉插管化疗栓塞的随机对照研究[J]. 第二军医大学学报, 2012,33(3): 274-279.
    [21]
    Yin L, Li H, Li AJ, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: A RCT[J]. J Hepatol, 2014, 61(1): 82-88.
    [22]
    常宗宏,汪泳,吴汉平. 肝癌的综合治疗及肿瘤抗血管联合疗法[J]. 世界华人消化杂志, 2012,20(5): 385-388.
    [23]
    Chung YH, Han G, Yoo JH, et al. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with Sorafenib in patients with hepatocellular carcinoma trial[J]. Int J Cancer, 2013,132(10): 2448-2458.
    [24]
    Kwok PC, Lam TW, Lam PW, et al. Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection ofhepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2003,18(4): 450-455.

Catalog

    Article views (224) PDF downloads (457) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return